Global Portfolio of Antimalarial Medicines

Translational

Preclinical
- GSK701 (GSK)
- NPC11618 (Mississippi)
- MK4815 (Merck)
- SCB3288 (Heidelberg University)
- Isoxazolines (Caliber Therapeutics)
- MMV370 (Janssen)
- MMV183 (Targea)
- MMV646 (Jardine)
- S011-1793 (CDRI)
- INE963 (Novartis)

Human volunteers
- P218 (Janssen)
- SJ733 (Kedrion/Esai)
- ACT-451840 (Iberisa)
- CDRI 9778 (Apotex)
- MS717 (Merck KGaA)
- MMV253 (Zydus Cadila)
- Atoguanil (Ipsen)
- MMV333 (Sanofi)
- SO11-1793 (CDRI)
- INE963 (Novartis)

Patient exploratory
- AQ13 (Imtech)
- Sevuparin (Modus Therapeutics)
- MMV048 (UCL)
- Rosiglitazone adjunct therapy (Mannova, Toronto, Barcelona)
- Imatinib (Novartis)
- Cipargamin (Novartis)
- Formidomycin (Piperaquine DMG, Deutsche Malaria GmbH)

Product development
- Ferroquine / Artesefenome (Sanofi)
- Dihydroartemisinin-piperazine dispersible (Alfaa)
- Co-trimoxazole (ITM Antwerp)
- Artemisinin-naphthoquine (Kingma Pharma Co)
- Artemether sub-lingual spray (MRC/Sha)
- Artemether-piperazine (Artemis)
- Tafenoquine paediatric (GSK)
- Sulfadoxine-pyrimethamine (Universal Corporation)
- Sulfadoxine-pyrimethamine (Swaziland/Soraran)
- Artemether-Lumefantrine <5kg (Novartis)

Patient confirmatory
- Dihydroartemisinin-piperazine dispersible (Alfaa)
- Co-trimoxazole (ITM Antwerp)
- Artemisinin-naphthoquine (Kingma Pharma Co)
- Artemether sub-lingual spray (MRC/Sha)
- Artemether-piperazine (Artemis)
- Tafenoquine paediatric (GSK)
- Sulfadoxine-pyrimethamine (Universal Corporation)
- Sulfadoxine-pyrimethamine (Swaziland/Soraran)
- Artemether-Lumefantrine <5kg (Novartis)

Regulatory review
- Dihydroartemisinin-piperazine dispersible (Alfaa)
- Co-trimoxazole (ITM Antwerp)
- Artemisinin-naphthoquine (Kingma Pharma Co)
- Artemether sub-lingual spray (MRC/Sha)
- Artemether-piperazine (Artemis)
- Tafenoquine paediatric (GSK)
- Sulfadoxine-pyrimethamine (Universal Corporation)

Access

Approved/ERP
- Artemether-lumefantrine (Various Manufacturers)
- Dihydroartemisinin-piperazine dispersible (Alfaa)
- Co-trimoxazole (ITM Antwerp)
- Artemisinin-naphthoquine (Kingma Pharma Co)
- Artemether sub-lingual spray (MRC/Sha)
- Artemether-piperazine (Artemis)
- Tafenoquine paediatric (GSK)
- Sulfadoxine-pyrimethamine (Universal Corporation)
- Sulfadoxine-pyrimethamine (Swaziland/Soraran)
- Artemether-Lumefantrine <5kg (Novartis)

MMV support to projects may include financial, in-kind, and advisory activities.

Footnotes:
- ☀️ Included in MMV portfolio after product approval and/or development.
- DNA and partners completed development and registration of ASMQ and ASAQ.
- Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
- WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
- ☀️ paediatric formulation.
- ☀️ via a bioequivalence study. Past partners are in brackets {}.
Footnotes: Global Portfolio

Target Product Profiles and Target Candidate Profiles


Target Product Profiles
indicated by bars at the bottom of each compound box

- 3-day cure, artemisinin-based combination therapies (TPP-1)
- Uncomplicated malaria treatments for single-exposure radical cure (SERC) and/or resistance management (TPP-1)
- Severe malaria treatment / pre-referral intervention (TPP-1)
- Intermittent preventive treatment (TPP-1)
- Products targeting prevention of relapse for P. vivax (TPP-1)
- Prophylaxis (TPP-2)

Target Candidate Profiles
activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio

- Asexual blood stages (TCP-1,2)
- Transmission reduction (TCP-3a)
- Causal prophylaxis (TCP-4)

Additional Symbols on Global Portfolio

- Brought into portfolio after approval; collaborations with DNDi
- No progress report in the last two years
- Global Fund Expert Review Panel (ERP) reviewed product — permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
- Paediatric formulation
- WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
- Approved in several countries but not approved by WHO pre-qualification nor regulatory bodies who are ICH members or observers
- MMV project or MMV-supported project

Footnote for Generic names on Global Portfolio

1. First approval: Novartis (Brand name: Coartem™). Generics by Ajanta, Cipla, Ipca, Strides Pharma, Macleods, Mylan
2. First approval: Novartis (Brand name: Coartem® Dispersible). Generics by Ajanta; Cipla; Strides Pharma; Ipca
3. Brand names: Artesun® (Fosun Pharma), Larinate® 60mg (Ipca)
4. First approval: Alfasigma (Brand name: Eurartesim®). Generic by Fosun Pharma
5. Brand name: Pyramax® tablets and granules
6. First approval fixed-dose combination: Sanofi/DNDi (Brand name: ASAQ Winthrop). Generics by Ajanta, Cipla, Fosun Pharma, Ipca, Strides Pharma, Macleods
7. Brand name: SPAQ-CO™, Supyra®
8. 100mg Artesunate Rectocaps
9. Artecap™
10. Brand names: Kozenis/Krintafel (Trademarks owned or licensed by GSK)
11. Brand names: ARAKODA™/KODATEF® (60 Degrees Pharmaceuticals)